Bioinformatics Analysis of Neuroblastoma MiRNA Based on GEO Data

Overview

Journal Pharmgenomics Pers Med

Publisher Dove Medical Press

Date 2021 Jul 21

PMID 34285553

Citations 6

Authors

Jiandong Shi

Piaoyan Zhang

Huarong Su

LingYi Cai

Liang Zhao

Haixia Zhou

Affiliations

Soon will be listed here.

Abstract

Objective: To analyze the changes in downstream genes, signaling pathways, and proteins based on the difference of microRNA (miRNA) expression in neuroblastoma (NB).

Methods: GSE128004 second-generation sequencing expression data were downloaded from GEO, and Limma package of R language was used to analyze differential expression, and a volcano map and heat map were drawn; the target genes corresponding to the differential miRNA were found using the miWalk web tool, and GO (Gene Ontology) and KEGG (Kyoto Encyclopedia of Genes and Genomes) were performed. The key genes were identified and verified in the TCGA database.

Results: A total of 34 differentially expressed miRNAs were screened out. Among them, 22 up-regulated miRNAs predicted 1163 target genes and 12 down-regulated miRNAs predicted 1474 target genes. Target genes were enriched and analyzed by KEGG to find the FOXO signal pathway, mTOR signal pathway, AMPK signal pathway, and other signal pathways. After GO analysis, axon formation, regulation of chemical synaptic transmitters, regulation of nerve synapses, regulation of cross-synaptic signals, and other physiological processes were assessed. A total of 16 key genes were obtained by PPI analysis, and the survival analysis of TP53 and ATM genes verified in the TCGA database showed statistical significance.

Conclusion: The 34 differential miRNAs may be related to the occurrence and development of NB. TP53 and ATM are related to the prognosis of NB. The role and mechanism of TP53 and ATM in NB need to be further verified.

Citing Articles

Construction and evaluation of a prognostic model of autophagy-related genes in hepatocellular carcinoma.

He Y, Du B, Liao W, Wang W, Su J, Guo C Biochem Biophys Rep. 2025; 41:101893.

PMID: 39760097 PMC: 11700244. DOI: 10.1016/j.bbrep.2024.101893.

MiR-1271-5p promotes the growth and migration of neuroblastoma cells by regulating ACY-1.

Sun J, Zhang X, Chen Z, Ye X, Zhang C Transl Cancer Res. 2024; 13(7):3397-3406.

PMID: 39145058 PMC: 11319971. DOI: 10.21037/tcr-24-25.

Analysis of High-Risk Neuroblastoma Transcriptome Reveals Gene Co-Expression Signatures and Functional Features.

Martinez-Pacheco M, Hernandez-Lemus E, Mejia C Biology (Basel). 2023; 12(9).

PMID: 37759629 PMC: 10525871. DOI: 10.3390/biology12091230.

Drugging Hijacked Kinase Pathways in Pediatric Oncology: Opportunities and Current Scenario.

Candido M, Medeiros M, Veronez L, Bastos D, Oliveira K, Pezuk J Pharmaceutics. 2023; 15(2).

PMID: 36839989 PMC: 9966033. DOI: 10.3390/pharmaceutics15020664.

Molecular Biology in Treatment Decision Processes-Neuro-Oncology Edition.

Krauze A, Camphausen K Int J Mol Sci. 2021; 22(24).

PMID: 34948075 PMC: 8703419. DOI: 10.3390/ijms222413278.

References

Bieerkehazhi S, Chen Z, Zhao Y, Yu Y, Zhang H, Vasudevan S . Novel Src/Abl tyrosine kinase inhibitor bosutinib suppresses neuroblastoma growth via inhibiting Src/Abl signaling. Oncotarget. 2016; 8(1):1469-1480. PMC: 5352070. DOI: 10.18632/oncotarget.13643. View

Zeka F, Decock A, Van Goethem A, Vanderheyden K, Demuynck F, Lammens T . Circulating microRNA biomarkers for metastatic disease in neuroblastoma patients. JCI Insight. 2018; 3(23). PMC: 6328024. DOI: 10.1172/jci.insight.97021. View

Salcher S, Spoden G, Hagenbuchner J, Fuhrer S, Kaserer T, Tollinger M . A drug library screen identifies Carbenoxolone as novel FOXO inhibitor that overcomes FOXO3-mediated chemoprotection in high-stage neuroblastoma. Oncogene. 2019; 39(5):1080-1097. PMC: 6989399. DOI: 10.1038/s41388-019-1044-7. View

Oh L, Hafsi H, Hainaut P, Ariffin H . p53, stem cell biology and childhood blastomas. Curr Opin Oncol. 2018; 31(2):84-91. DOI: 10.1097/CCO.0000000000000504. View

Ritchie M, Phipson B, Wu D, Hu Y, Law C, Shi W . limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015; 43(7):e47. PMC: 4402510. DOI: 10.1093/nar/gkv007. View

Lin A, Hua R, Tang J, Zhu J, Zhang R, Zhou H . rs7973450 A>G increases neuroblastoma risk in Chinese children: a four-center case-control study. Onco Targets Ther. 2019; 12:7289-7295. PMC: 6733352. DOI: 10.2147/OTT.S223220. View

Kostopoulou O, Holzhauser S, Lange B, Ohmayer A, Andonova T, Bersani C . Analyses of FGFR3 and PIK3CA mutations in neuroblastomas and the effects of the corresponding inhibitors on neuroblastoma cell lines. Int J Oncol. 2019; 55(6):1372-1384. DOI: 10.3892/ijo.2019.4896. View

Mei H, Wang Y, Lin Z, Tong Q . The mTOR signaling pathway in pediatric neuroblastoma. Pediatr Hematol Oncol. 2013; 30(7):605-15. DOI: 10.3109/08880018.2013.798058. View

Kiessling M, Rogler G . Targeting the RAS pathway by mitogen-activated protein kinase inhibitors. Swiss Med Wkly. 2015; 145:w14207. DOI: 10.4414/smw.2015.14207. View

10.

Geiger K, Hagenbuchner J, Rupp M, Fiegl H, Sergi C, Meister B . FOXO3/FKHRL1 is activated by 5-aza-2-deoxycytidine and induces silenced caspase-8 in neuroblastoma. Mol Biol Cell. 2012; 23(11):2226-34. PMC: 3364184. DOI: 10.1091/mbc.E11-06-0535. View

11.

Veschi V, Thiele C . High-SETD8 inactivates p53 in neuroblastoma. Oncoscience. 2017; 4(3-4):21-22. PMC: 5441469. DOI: 10.18632/oncoscience.344. View

12.

Matthay K, Maris J, Schleiermacher G, Nakagawara A, Mackall C, Diller L . Neuroblastoma. Nat Rev Dis Primers. 2016; 2:16078. DOI: 10.1038/nrdp.2016.78. View

13.

Mlakar V, Jurkovic Mlakar S, Lesne L, Marino D, Rathi K, Maris J . PRIMA-1-induced neuroblastoma cell death is modulated by p53 and mycn through glutathione level. J Exp Clin Cancer Res. 2019; 38(1):69. PMC: 6373164. DOI: 10.1186/s13046-019-1066-6. View

14.

Mao X, Chen Z, Zhao Y, Yu Y, Guan S, Woodfield S . Novel multi-targeted ErbB family inhibitor afatinib blocks EGF-induced signaling and induces apoptosis in neuroblastoma. Oncotarget. 2016; 8(1):1555-1568. PMC: 5352076. DOI: 10.18632/oncotarget.13657. View

15.

Richards K, Zweidler-McKay P, Van Roy N, Speleman F, Trevino J, Zage P . Signaling of ERBB receptor tyrosine kinases promotes neuroblastoma growth in vitro and in vivo. Cancer. 2010; 116(13):3233-43. PMC: 2923448. DOI: 10.1002/cncr.25073. View

16.

Rupaimoole R, Slack F . MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017; 16(3):203-222. DOI: 10.1038/nrd.2016.246. View

17.

Pottoo F, Abul Barkat M, Harshita , Ansari M, Noushad Javed M, Jamal Q . Nanotechnological based miRNA intervention in the therapeutic management of neuroblastoma. Semin Cancer Biol. 2019; 69:100-108. DOI: 10.1016/j.semcancer.2019.09.017. View

18.

Yu G, Wang L, Han Y, He Q . clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012; 16(5):284-7. PMC: 3339379. DOI: 10.1089/omi.2011.0118. View

19.

Pugh T, Morozova O, Attiyeh E, Asgharzadeh S, Wei J, Auclair D . The genetic landscape of high-risk neuroblastoma. Nat Genet. 2013; 45(3):279-84. PMC: 3682833. DOI: 10.1038/ng.2529. View

20.

Izycka-Swieszewska E, Brzeskwiniewicz M, Wozniak A, Drozynska E, Grajkowska W, Perek D . EGFR, PIK3CA and PTEN gene status and their protein product expression in neuroblastic tumours. Folia Neuropathol. 2011; 48(4):238-45. View